Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 370 (25), 2397-407

Antidepressant Use in Pregnancy and the Risk of Cardiac Defects

Affiliations
Comparative Study

Antidepressant Use in Pregnancy and the Risk of Cardiac Defects

Krista F Huybrechts et al. N Engl J Med.

Abstract

Background: Whether the use of selective serotonin-reuptake inhibitors (SSRIs) and other antidepressants during pregnancy is associated with an increased risk of congenital cardiac defects is uncertain. In particular, there are concerns about a possible association between paroxetine use and right ventricular outflow tract obstruction and between sertraline use and ventricular septal defects.

Methods: We performed a cohort study nested in the nationwide Medicaid Analytic eXtract for the period 2000 through 2007. The study included 949,504 pregnant women who were enrolled in Medicaid during the period from 3 months before the last menstrual period through 1 month after delivery and their liveborn infants. We compared the risk of major cardiac defects among infants born to women who took antidepressants during the first trimester with the risk among infants born to women who did not use antidepressants, with an unadjusted analysis and analyses that restricted the cohort to women with depression and that used propensity-score adjustment to control for depression severity and other potential confounders.

Results: A total of 64,389 women (6.8%) used antidepressants during the first trimester. Overall, 6403 infants who were not exposed to antidepressants were born with a cardiac defect (72.3 infants with a cardiac defect per 10,000 infants), as compared with 580 infants with exposure (90.1 per 10,000 infants). Associations between antidepressant use and cardiac defects were attenuated with increasing levels of adjustment for confounding. The relative risks of any cardiac defect with the use of SSRIs were 1.25 (95% confidence interval [CI], 1.13 to 1.38) in the unadjusted analysis, 1.12 (95% CI, 1.00 to 1.26) in the analysis restricted to women with depression, and 1.06 (95% CI, 0.93 to 1.22) in the fully adjusted analysis restricted to women with depression. We found no significant association between the use of paroxetine and right ventricular outflow tract obstruction (relative risk, 1.07; 95% CI, 0.59 to 1.93) or between the use of sertraline and ventricular septal defects (relative risk, 1.04; 95% CI, 0.76 to 1.41).

Conclusions: The results of this large, population-based cohort study suggested no substantial increase in the risk of cardiac malformations attributable to antidepressant use during the first trimester. (Funded by the Agency for Healthcare Research and Quality and the National Institutes of Health.).

Figures

Figure 1
Figure 1
Relative risks and 95% confidence intervals comparing the risk of any cardiac malformation for women with and without antidepressant exposure during the first trimester; unadjusted, restricted to women with depression, and using PS stratification for confounding adjustment. Medicaid Analytic eXtract 2000–2007.
Figure 2
Figure 2
Relative risks and 95% confidence intervals comparing the risk of specific cardiac malformations for women with and without antidepressant exposure during the first trimester; unadjusted, restricted to women with depression, and using PS stratification for confounding adjustment. Medicaid Analytic eXtract 2000–2007.

Comment in

Similar articles

See all similar articles

Cited by 75 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback